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The first day of this research summit
reviewed the evidence that both innate
and acquired immunity are involved in
alopecia areata (AA). Genetic and func-
tional immunologic studies have identi-
fied complex immunologic networks in
both human and animal model AA.
Natural killer group 2D ligands, IL-15,
cytotoxic T-lymphocyte antigen-4, and
Janus kinase signaling have emerged
as attractive targets for treatment of
AA using modern biologic and pharma-
cologic approaches. Modulation of
immune privilege continues to be an
intriguing target to modulate AA induc-
tion and progression. The specificity of
the immune response in AA is still
unknown. Pigmented anagen hair folli-
cles appear to be the target. Whether
antigen-specific activated T cells or anti-
bodies are required for AA is not yet
known. Development of a robust clin-
ical research platform will facilitate the
testing of a number of new drugs being
effectively used in other autoimmune
diseases.
Genetics of Alopecia Areata
As the approaches to studying the genet-
ics of alopecia areata (AA) have broa-
dened from linkage studies in families,
to genome-wide association studies, to
deep sequencing of key areas of the
genome, it has been increasingly clear
that genetic control of innate and
acquired immunity is the most powerful
factor in determining the susceptibility
to all variants of AA, from patchy dis-
ease to alopecia universalis. There are
four major genetics questions that were
addressed during the first day of this
Research Summit:
1. Which genes act as ‘‘drivers’’ of
disease and which are merely
‘‘enablers’’?
2. Is there a genetic basis for disease
subsets?
3. What are the key genes in control of
disease?
4. What is the genetic relationship to
other autoimmune diseases?
Angela Christiano, PhD, Columbia
University, reviewed the significant
progress since the publication of the
groundbreaking first GWAS study in
AA (Petukhova et al., 2010). Another
group has validated the genes found in
the previous study, and Dr Christiano
has identified further important immune
response genes in a second association
study: PTPN22, PTPN2, IRG, IL-13, IL-4,
and IFN signature. Associated gene
products in hair follicle in AA (STX 17,
PRDX5, ULBP6, and ULBP3) provide
important clues to possible initiation of
disease, and may be therapeutic targets.
Importantly, there is not much genetic
overlap with either psoriasis or vitiligo,
although there are five loci shared bet-
ween AA and type 1 diabetes. Future
genetic studies underway include
combination of association and linkage
studies using the 250 multiplex families
in the registry, functional genomics,
deep sequencing, and development of
a human network plot.
Immunologic Parameters in AA
It is clear that complementary functional
immunologic studies are necessary
to characterize the pathways in AA,
validating network components identi-
fied in genetics studies. The important
questions now under consideration
include:
(1) What is the balance of innate and
acquired immunity?
(2) What are attractive pathways for
targeted therapy?
(3) What is the specificity of the imm-
une response?
(4) What is the role for loss of immune
privilege in initiation and mainte-
nance of disease?
(5) What animal model best serves the
research needs in AA?
Immunologic Networks in AA
The seminal first GWAS study in AA
(Petukhova et al., 2010) identified multi-
ple genes that controlled both acquired
and innate immunity. Raphael Clynes,
MD, PhD, Columbia University, repor-
ted on exciting new efforts to delineate
the pathways that activate innate and
acquired immunity in AA, opening
exciting new opportunities for targeted
immunotherapy (Petukhova et al., 2011)
(summarized in Table 2). He proposes
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that natural killer group 2D (NKG2D)
ligands activate natural killer (NK) T
cells (NKG2DþCD8þ ) to attack the
cells of the hair bulb. Signaling path-
ways containing IL-15, IRB, and Janus
kinase (JAK) 1/3 lead to the activation of
cytotoxic T cells, activation of memory
T cells, and downregulation of
regulatory T cells. NKG2D–activating
ligands and IL-15 can be found in AA
hair follicle bulbs, and may provide the
key response to danger signals that
initiate AA. Previous studies by John P
Sundberg, DVM, PhD, The Jackson
Laboratory, and more recent studies
by Drs Clynes and Christiano have
shown impressive functional similarities
between human AA and the C3H/HeJ
mouse model. They have similar appar-
ent end-organ drivers (NKG2DL
(ULBP3, MICA) and IL-15 in HF), similar
effectors (CD8 T-cell effectors), and
similar biomarkers (IFN gene signatures),
arguing for the importance of transla-
tional studies in this mouse model. In
this model, IL-15 inhibitors block the
development of AA, and NKG2Dþ
CD8þT cells are the key to transfer of
disease. Clynes and co-workers are
effectively using the C3H/HeJ mouse to
test new treatment approaches, includ-
ing anti-CTLA-4 (cytotoxic T-lympho-
cyte antigen-4) biologics, JAK
inhibitors, and IL-15 inhibitors.
The combination of GWAS studies,
functional immunology, and the mobi-
lization of the C3H/HeJ mouse model
has placed us on the threshold of revo-
lutionary changes in the treatment of
AA. John Sundberg produced additional
information of the impact of animal
models in AA research. GWAS studies
in the C3H/HeJ mouse have shown the
importance of IL-1/IL-18, CH17 cells,
and TAP2/TAP1 upstream from CD8
and NK cells.
Ralf Paus, University of Luebeck Ger-
many/University of Manchester, UK,
provided a thoughtful review of the
current thinking on the loss of immune
privilege in AA. He believes that the
hair follicle bulb and bulge both
enjoy immune privilege because of
low expression of Class I and Class II
HLA antigens, associated with high
expression of a-melanocyte-stimulating
hormone and transforming growth fac-
torB2. In AA, CD8þ cells enter the hair
follicle epithelial zone of the bulb, but
only with the upregulation of HLA class
antigen expression in the hair bulb. This
is associated with five phenomena: loss
of tolerance, collapse of immune privi-
lege (IFNg dependent), presentation of
sequestered autoantigen, entry of hair
follicle into anagen, and costimulatory
signals from CD4þ cells and mast cells.
He raises the possibility that sensitiza-
tion of T cells to hair follicle antigens
may NOT be necessary in AA. Dr Paus
proposes that drugs that return immune
privilege may be able to reverse AA, e.g.
melanocyte-stimulating hormone ana-
logs and tacrolimus.




NKG2D ligands: ULBP6, ULBP3, MICA
(expressed in AA biopsies in the hair bulb region)
Cytokine
Acquired immunity
Antigen presentation: HLA-DRA, HLA-DQA1, HLA-DQA2, HLA-DQB2, HLA-DOB9
(actually there are 44 HLA genes with significant association)
T cell proliferation: CTLA-4, ICOS, IL-21, IL-2, IL-2RA, IKZF4, BTNL2
T cell differentiation: Notch 4
Tregs: CTLA-4, IKZF4, IL-2, IL-2RA
End organ
Antioxidant: PRDX5
Premature graying: STX 17
Abbreviations: AA, alopecia areata; CTLA-4, cytotoxic T-lymphocyte antigen-4; NKG2D, natural killer
group 2D; PRDX5, peroxiredoxin-5; STX 17, syntaxin 17; Tregs, regulatory T cells.




MICA, UBLP-3, UBLP-6, Rae-1
First responders
DETC, NK, NKT, g( )d T
APC/sentinel
Cellular sentinels: Langerhans cells, dermal dendritic cells, dermal macrophage, mast cells
Determinants: HLA, TAP, IFN-g
Adaptive immunity
Immune cells: CD4þ T cells, CD8þT cells, Treg, B cells
CTLA-4, iCOS, IL-2, IL-2R, IL-2R, IL-21
Cytokine network: IL-2, IL-6, IL-17, IL-21, IFN-g, IFN-a
Downstream signaling pathways: JAK 1/2, Syk
Abbreviations: AA, alopecia areata; APC, antigen-presenting cell; CTLA-4, cytotoxic T-lymphocyte
antigen 4; iCOS, inducible costimulator; JAK, Janus kinase; NKG2D, natural killer group 2D; TAP,
transporter associated with antigen processing; TNF, tumor necrosis factor; Treg, regulatory T cells.
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Thomas Waldmann, MD, National
Institutes of Health, produced further
perspectives on the great potential of
IL-15 modulation in treating cancer and
inflammatory diseases. IL-2 and IL-15
have contrasting role in the life of a
T cell: IL-2 provides checkpoint control
of T cells required for self-tolerance
and prevention of autoimmunity. IL-15
favors survival of memory CD8 cells.
IL-15 expands CD8 and, to a lesser
extent, NK cells, and is effective in
cancer models. Antibody-mediated
blockade of IL-15 is an effective
inhibitor of autoimmunity, e.g. in a celiac
disease model. IL-15 blockade has nar-
row effects, whereas JAK inhibition pro-
duces broader effects and side effects.
Amos Gilhar, MD, Technion-Israel
Institute of Technology and Flieman
Medical Center, has been responsible
for some of the fundamental studies
establishing AA as an autoimmune dis-
ease mediated by CD4 and CD8 T cells.
His most recent animal model extends
these findings, showing the importance
of CD8þNK2GDþ cells in AA model-
ing. In his new model, peripheral blood
mononuclear cell from AA patients are
stimulated in vitro with high IL-2 (not
hair follicle antigens), and then are
injected into mice grafted with hair-
bearing human skin. Hair loss occurred
in both allogeneic and autologous skin
grafts. Biopsies for alopecic skin showed
CD4 and CD8 cells, dense NKG2D
cells, and prominent NKG2D cells. This
model raises questions about the effec-
tor cells in AA, and whether antigen-
sensitized T cells are indeed necessary.
Depletion of CD56þ cells blocked
induction of alopecia.
Annemieke DeJong, PhD, Columbia
University, presented her preliminary
studies to identify clonal T cell popula-
tions in AA patients and in the C3H/HeJ
mouse model. The goal was to answer
three questions:
(1) Does clonal expansion occur?
(2) Are pathogenic T cells in the per-
ipheral blood?
(3) Do pathogenic T cells in circulation
express markers that can be used as
biomarkers?
Some clones in the skin were also
found in peripheral blood in alopecia
universalis patients, but not in patchy
persistent AA. In C3H/HeJ mice engrafted
with alopecic skin from other syngeneic
mice, the grafted skin contained patho-
genic clones, and CD8þNKG2Dþ
cells were found in skin draining lymph
nodes. Clonal expansion was observed
and clones were found in the peripheral
blood. The power of parallel experiments
in human and mouse AA was once again
demonstrated.
Development of Clinical Research
Platform in AA
Ali Jabbari, MD, PhD, Columbia Uni-
versity, also presented an exciting recent
program—development of a robust clin-
ical research platform for clinical trials
in AA. There are several problems that
stand in the way of developing strong
clinical research programs in AA: diffi-
culty in recruiting patients, high and
unpredictable levels of spontaneous
regression of AA, and lack of biomarkers
that can be used to measure response
in parallel to measurement of hair
regrowth. The developing research plat-
form will include sampling of skin,
serum, and peripheral blood mononuc-
lear cell for known markers of immune
response, and or skin RNA and micro-
RNA for gene expression studies. Paral-
lel studies in humans and mice are
underway, and both systemic, topical,
and intralesional drug delivery will be
tested to validate response end points
and biomarker usefulness.
Amelia Wall Warner, PharmD,
RPh, Merck Research Laboratories, fin-
ished this first day of the Summit with
observations on the role of pharmaco-
genomics in AA drug development.
Pharmacogenomics provides the oppor-
tunity to predict which patients will
respond and which will not. Whole-
exome and whole-genome sequencing
provides the opportunity to obtain and
study massive amounts of genetic data.
The growth of personalized medicine
promises to establish which genes are
drivers of disease and which are merely
enablers. Pharmacogenomics promises
to provide ways to identify subsets of
disease, and to predict treatments for
different subsets.
Conclusion
The first day of this Research Summit
provided considerable evidence that the
key questions proposed at the beginning
of this summary are now being
addressed with modern research techni-
ques. We now know that
(1) Both innate and acquired immunity
are involved in AA.
(2) Both genetic and functional immu-
nologic studies have identified com-
plex immunologic networks in
both human and animal model
AA. NKG2D ligands, IL-15, CTLA-4,
and JAK signaling have emerged as
attractive targets for treatment of AA
using modern biologic and pharma-
cologic approaches.
(3) Modulation of immune privilege
continues to be an intriguing target
to modulate AA induction and
progression.
(4) The specificity of the immune
response in AA is still unknown.
Pigmented anagen hair follicles
appear to be the target. Whether
antigen-specific activated T cells or
antibodies are required for AA is not
yet known.
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